Earlier this week, researchers from across the Microbiome Health Initiative (MHI) convened for the first time. This collaborative effort, supported by the Novo Nordisk Foundation, aims to explore potential causal links between the gut microbiome—the collective genetic material of bacteria and other microbes in the human gut—and the development of cardiometabolic diseases (CMD), including obesity, type 2 diabetes, and cardiovascular disease.

The overarching goal of the initiative is to generate insights that could pave the way for novel prevention strategies and treatment options for individuals living with, or at risk of, CMD.

This first meeting provided a valuable opportunity to connect the diverse expertise within the collaboration and to align on the scientific questions ahead. Beyond the scientific discussions, the event also focused on team-building, with networking activities and a cozy evening by the bonfire.

The meeting took place in the scenic surroundings of KolleKolle in Værløse, Denmark. Our group was proudly represented by Annika, Valentina, Louise and Katharina. Fredrik participated in a dual role—both as a leader of our research group and as Director of the MHI.